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Abstract: Background and aim: Translational data suggest that
 
nucleoside transporters, in particular human equilibrative 
nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome
 
after gemcitabine chemotherapy 
for several types of cancer. The aim of this study was to retrospectively determine patients’ outcome according to the ex-
pression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy.  
Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with un-
resectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens.  
Results: Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical 
analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and 
hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) 
(p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with 
positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median 
overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this dif-
ference did not reach the statistical significance (p=0.128).  
Conclusions: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in pa-
tients with advanced BTC. 
Keywords: Biliary tract cancer, gemcitabine, hENT1, predictive factor. 
INTRODUCTION 
Biliary tract cancers (BTCs) are rare tumors and repre-
sent a major challenge for surgical, medical, and radiation 
oncologists. Unfortunately, the majority of these tumours are 
not resectable at the time of initial diagnosis, and patients 
with advanced disease show a poor prognosis. The efficacy 
of conventional cytotoxic agents (e.g., 5-fluorouracil, mito-
mycin-C, and cisplatin) seems to be low, and currently there 
is no agreement about the optimal chemotherapeutic regimen 
in this setting [1]. 
The nucleoside pyrimidine analogue gemcitabine is the 
most effective single agent in advanced BTCs, where it has 
been shown to improve clinical symptoms and to modestly 
extend survival [2]. Gemcitabine appears to be a reasonable 
alternative to the best supportive care in this setting, on the 
basis of encouraging results in non-randomized clinical stud-
ies [2,3]. For the first time, at the 2009 American Soci- 
 
 
*Address correspondence to this author at the Department of Medical On-
cology, University Campus Bio-Medico, Via Alvaro del Portillo, 200 00128 
Roma, Italy; Tel: + 39-06-225411242; Fax: +39-06-225411936;  
E-mail: d.santini@unicampus.it 
ety of Clinical Oncology Annual meeting, the final results of 
a phase III randomized trial comparing gemcitabine with or 
without cisplatin have been presented. This study showed a 
statistical significant advantage of the gemcitabine-based 
doublet in terms of progression free survival (PFS) and me-
dian survival
1
. Consequently, chemotherapy with a combina-
tion of gemcitabine and cisplatin represents the new standard 
of therapy in advanced BTCs. Because the biochemical tar-
gets of gemcitabine are intracellular, the translocation 
through the plasma membrane is a necessary step for the 
drug to exert its cytotoxic effect. Gemcitabine is a hydro-
philic molecule
 
and does not cross the plasma membrane by 
diffusion. In fact, an efficient cellular uptake requires the 
presence
 
of specialized plasma membrane nucleoside trans-
porter (NT) proteins [4]. The human equilibrative nucleoside 
transporter 1 (hENT1) is a ubiquitous protein and is the ma-
jor transporter by which gemcitabine
 
enters cultured human 
cells and hematopoietic
 
progenitor cells [5]. The abundance 
and distribution of hENT1 protein can be evaluated using 
immunohistochemistry, and it has been already assessed in a 
                                            
1Furuse, J.; Okusaka, T.; Miyazaki, M.; Taniai, H.; Nimura, Y. A randomized study of 
gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract 
cancer. J. Clin. Oncol. 2009, 27(15s), Abstr 4579. 
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number of malignant and benign tissues [6-9]. Interestingly, 
immunohistochemical (IHC) variations of hENT1 in pancre-
atic adenocarcinoma samples significantly correlate with 
median survival after gemcitabine therapy in patients with 
advanced disease [10]. Moreover, IHC analysis of hENT1 
has recently been shown to be predictive of benefit from 
gemcitabine chemotherapy in resected pancreatic cancers 
[11]. 
There are limited data about hENT1 in BTCs. Studies in-
volving BTC cells (OCUG-1 and HuCTT1) have indicated 
that hENT1 is overexpressed and it is the major gemcitabine 
transporter, representing the most important determinant of 
gemcitabine sensitivity [12]. Our research group has recently 
demonstrated that hENT1 is expressed in about 30% of am-
pullary cancers and its expression provides prognostic in-
formation in this type of patients [13]. 
The role of hENT1 expression in predicting the activity 
of a gemcitabine-based chemotherapy in advanced BTCs is 
lacking in literature.  
Considering this scenario, we studied the expression of 
hENT1 by IHC analysis in tumour samples from 31 BTC 
patients receiving a gemcitabine-based therapy and we corre-
lated these biological results with clinical outcome.  
MATERIALS AND METHODS 
Clinical Data and Tumour Specimen Acquisition 
The analysis was performed on samples from 31 patients 
with unresectable locally advanced or metastatic BTC con- 
secutively treated with gemcitabine-based regimens between 
June 2001 and June 2008 in four Italian oncological centers. 
Adequate tumour biopsy specimens obtained before starting 
a gemcitabine-based chemotherapy were available for all the 
patients. Permission to perform this study was obtained by 
the local ethical board. The histopathological classification 
was based on WHO guidelines. Clinical staging was based 
on an initial evaluation consisting of a clinical assessment, 
computed tomography (CT) of the chest and abdomen and 
magnetic resonance imaging (MRI) of the abdomen. TNM 
classification (as reported in the ESMO Clinical Recommen- 
dation for diagnosis, treatment and follow-up) was used for 
the clinical staging [14]. The clinicopathological characteris- 
tics of all the patients are listed in Table 1. The patient popu- 
lation included 18 males and 13 females, with a median age 
of 70 (range, 52—83 years). 
All specimens underwent a gross anatomical examination 
according to the procedure described by Rosai [15], includ-
ing the evaluation of all the anatomical structures. Response 
was evaluated in patients who had received at least two or 
more courses of chemotherapy, using standard response cri-
teria. Response evaluation has been performed after two or 
three cycles (6–9 weeks) of chemotherapy
 
by clinical evalua-
tion, blood
 
tests and by repeating the initially abnormal radi-
ologic examinations [14]. Complete response was defined as 
the disappearance of all signs of disease both at clinical and 
radiological examination. Partial response was defined by a 
reduction of more than 50% in the sum of products of the 
largest perpendicular diameters of all tumour localizations, 
with absence of new tumour lesions. Stable disease was de-
fined as a reduction of less than 50% or an increase less than 
Table 1. Patients’ Characteristics 
 
  # tot Patients  (%) 
  31 
Gender M 18 (58.1) 
 F 13 (41.9) 
 Performance status (ECOG) 0 25 (80.6) 
 1 6 (19.4) 
Age (ys) Median (Range) 70 (50-86) 
 <65 12 (38.7) 
 65 19 (61.3) 
Primary Tumor location Gall bladder 9 (29) 
 Ampulla 5 (16.1) 
 Intraepatic biliary tract 4 (12.9) 
 Extraepatic biliary tract 13 (42) 
Chemotherapy Gem + Capecitabine 18 (58.1) 
 Gem + Oxaliplatin 4 (12.9) 
 
Gem + Fluorouracil 
Gem alone 
1 (3.2) 
8 (25.8) 
TTP (months) Median 4.83 ms 
OS (months) Median  13.33 ms 
F: female, Gem: gemcitabine, M: male, ms: months, OS: overall survival, TTP: time to progression. 
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25% of tumour lesions. Tumour progression was defined as 
an increase more than 25% in the size of tumour lesions or 
the appearance of a new lesion.  
Tissue Preparation and Immunostaining 
Representative tumour blocks were sectioned at 3 m 
thickness for IHC studies. The sections were deparaffinized 
with three immersions in xylene baths (10 minutes each) 
followed by serial washes in graded alcohol from 100 to 
50%. After rinsing in water, slides were placed in 250 mL of 
high pH 1X DAKO target antigen retrieval solution and mi-
crowaved in TT-mega Milestone (ESBE Scientific, Mark-
ham, Ontario, Canada) under controlled temperature and 
high pressure for 10 minutes at 100°C. After cooling in wa-
ter for 6 minutes, slides were rinsed with water and peroxi-
dase blocked in 3% hydrogen peroxide solution with metha-
nol for 10 minutes then washed in running water for 10 min-
utes. PBS (pH 7.2) was used for rinsing before incubation in 
a humidified chamber overnight at 4°C with appropriate di-
lutions of anti-hENT1 mouse monoclonal antibody devel-
oped and characterized as described previously [13]. Then, 
sections were rinsed with PBS, immersed in buffer for 5 
minutes, incubated with goat anti-mouse dextran conjugate 
(DAKO Envision) for 30 minutes, followed by soaking in 
PBS. DAKO diaminobenzidine liquid chromagen was placed 
on the samples for 5 minutes, then rinsed, after which the 
slides were soaked in 1% CuSO4 for 5 minutes. Subse-
quently, the sections were rinsed, counterstained with hema-
toxylin, dehydrated through graded alcohol and xylene, and 
finally coverslipped. Negative controls were provided by 
omitting the primary antibody. Immunostaining was assessed 
by two independent pathologists blinded to clinical charac-
teristics and outcomes. 
Scoring for hENT1 was based on relative intensities of 
staining of the biliary tract tumor with reference to the nor-
mally present hENT1 staining of cell membranes of lympho-
cytes. These internal references were then used as internal 
positive controls between slides and samples as well as for 
the staining procedure. Biliary tract tumor tissue was then 
evaluated by comparison with the internal controls.  
A three-point scale has been used for qualitatively scor-
ing the intensity of staining, where 0 (absent or negative) 
indicates no staining, 1+ (weak) indicates positive staining 
but less intense than or equal to the positive internal control 
and 2+ (strong) indicates positive staining more intense than 
the positive internal control. 
Samples with regions of varying staining intensities of 
hENT1 were scored and the percentages of each staining 
intensity were recorded (Fig. 1). 
The final hENT1 score for each sample was negative (in 
case of “score 0”  50% of cells) or positive (in case of 
“score 0”< 50% of cells and any percentage of “score 1+” 
and/or “score 2+”). 
Statistical Analysis 
The following clinical characteristics and variables were 
considered and so categorized: age (<65 vs 65), gender 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Illustrations for the hENT1 staining. The positive staining in the infiltrating lymphocytes served as a positive internal control. A 
three-point scale has been used for qualitatively scoring the intensity of staining, where 0 (absent or negative) indicates no staining, 1+ 
(weak) indicates positive staining but less intense than or equal to the positive internal control and 2+ (strong) indicates positive staining 
more intense than the positive internal control.  
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(male vs female), performance status (ECOG 0 vs 1) and 
primary tumor location (gall bladder vs ampulla vs intrahe-
patic biliary tract vs extrahepatic biliary tract). Clinical re-
sponse after three cycles of chemotherapy has been evalu-
ated (progressive disease versus stable disease versus partial 
response). Regarding toxicities, the worst hematologic and 
non-hematologic have been also dichotomized (grades 1, 2 
vs grade 3 or higher). 
hENT1 expression was dichotomized as negative vs posi-
tive. 
Fisher's exact test and Chi-square test for trend were ap-
plied to assess the association between hENT1 expression 
and the above mentioned baseline clinical characteristics and 
variables. 
Time to progression (TTP) was considered as the period 
of time from the starting date of the treatment to the first 
observation of disease progression. The overall survival (OS) 
time was calculated
 
as the period of time from the starting 
date of the treatment until death for
 
any cause or until the last 
follow-up. Univariate analysis for correlation between sur-
vival (TTP and OS) and both clinical variables and hENT1 
expression, was estimated by the Kaplan-Meier method and 
groups were compared by the log-rank test. Moreover, re-
sults were expressed as Hazard Ratio (HR).  
P values <0.05 were considered statistically significant in 
two-tailed tests. Prism 5 (GraphPad Software, Inc.) was used 
to perform the statistical analysis. 
RESULTS 
Patient Population 
Primary sites were so distributed: intrahepatic biliary 
tract in 4 patients (12.9%); extrahepatic biliary tract in 13 
patients (42%); gall bladder in 9 patients (29%); ampulla in 5 
patients (16.1%). All the patients were treated with gemcit-
abine, either alone or in combination, mostly with capecit-
abine or oxaliplatin, and less often with fluorouracil. The 
median of cycles received was 11 (range 3-20). The median 
survival from initiation of gemcitabine chemotherapy was 
13.33 months and the median TTP was 4.83 months.  
After obtaining informed consent in accordance with in-
stitutional guidelines, all the patients underwent a tumor bi-
opsy followed by chemotherapy. 
Table 2. Correlations Between Immunohistochemical Data and Clinical, Pathological and Therapeutic Data 
 
  hENT1 neg hENT1 pos p value 
 # of patients (%)  10 (32.3) 21 (67.7)  
Gender M 6 12 ns* 
 F 4 9  
 Performance status 0 4 11 ns* 
(ECOG) 1 0 3  
Age (ys) Median (Range) 67 71  
 <65 5 7 ns* 
 65 5 14  
Primary Tumor location Gall bladder 2 7 0.4138** 
 Ampulla 2 3  
 Intrahepatic biliary tract 0 4  
 Extrahepatic biliary tract 6 7  
Clinical Response  PD 4 8 0.7353** 
(3
rd
 cycle of CTX) SD 1 5  
 PR 3 8  
Non-hematologic  toxicity G0-G2 2 12 ns* 
 (WHO) G3-G4 2 2  
Hematologic toxicity G0-G2 4 11 ns* 
(WHO) G3-G4 0 3  
TTP (months) Median 2.83 ms 6.33 ms 0.03 (HR 2.9)*** 
 95% CI   1.05-7.99 
OS (months) Median  7 ms 14 ms 0.12 (HR 2.08)*** 
 95% CI   0.8-5.34 
CTX: chemotherapy, F: female, M: male, ms: months, ns: not significant, OS: overall survival, PD: progressive disease, PR: partial response, SD: stable disease, TTP: time to pro-
gression, ys: years. 
*Fisher's exact test, ** Chi-square test for trend, ***Log-rank (Mantel-Cox) Test. 
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Immunohistochemical Data 
Tumor samples of all 31 patients have been evaluated for 
hENT1 immunohistochemistry. The localization of the 
hENT1 immunostaining was predominantly at plasma mem-
brane, although a cytoplasmic staining was occasionally ob-
served. Positive hENT1 staining patients were 21 (67.7%), 
negative hENT1 staining patients were 10 (32.3%). Distribu-
tion of hENT1 immunostainig in different histotypes (posi-
tive/negative) was: gallbladder (7/2); ampulla (3/2); intrahe-
patic BTC (4/0); extrahepatic BTC (7/6). 
Correlations Between Immunohistochemical Data and 
Clinical Outcome 
To study a possible correlation between immunohisto-
chemical data and patient outcome, tumor samples were 
classified as positive or negative for hENT1.  
At the time of analysis (June 2009), after a median fol-
low-up of 13 months, 25 (80.6%) patients were dead and 6 
(19.4%) patients were alive. Overall, 28 (90.3%) patients 
progressed under a gemcitabine-based chemotherapy and 
only 3 (9.7%) patients, at the time of the statistical analysis, 
were on therapy with gemcitabine.  
There was not statistical association between baseline 
characteristics (age, gender, ECOG performance status and 
site of primary tumor) and hENT1 levels. Moreover, there 
was not statistical association between toxicities (hema-
tologic and non-hematologic) and hENT1 levels (Table 2). 
Finally, we did not find any statistically significant correla-
tion between hENT1 protein staining and tumor response to 
gemcitabine based regimens (p=0.735) (Table 2). On the 
other hand, hENT1 protein staining was significantly associ-
ated with TTP in the univariate analysis. There was an im-
provement in TTP for positive hENT1 staining patients (HR: 
2.902; 95% CI, 1.053-7.996; p=0.03). Specifically, the me-
dian TTP in positive hENT1 staining patients was 6.33 
months, as compared to only 2.83 months in those with low 
hENT1 expression (p=0.03) (Table 2) (Fig. 2). Furthermore, 
those patients with overexpression of hENT1 showed a 
longer OS when compared with patients with low hENT1 
levels, but this increase did not reach the statistical signifi-
cance (HR: 2.08; 95% CI, 0.809-5.345; p=0.12). Specifi-
cally, the median OS in positive hENT1 staining patients 
was 14.0 months, as compared to only 7.0 months in those 
with low hENT1 expression (p=0.12) (Table 2) (Fig. 3). 
Then, we correlated the hENT1 levels of the 18 patients 
treated with gemcitabine at fixed dose rate and capecitabine 
with TTP and OS. In this specific subgroup of patients 
hENT1 protein staining was significantly associated also 
with OS (18.8 months in hENT1 positive vs 6.5 months in 
hENT1 negative patients) (HR: 8.024; 95% CI, 1.36-47.30; 
p=0.02).  
In conclusion, besides hENT1 staining, none of the other 
parameters considered produced a separation in the survival 
curves after gemcitabine initiation. 
DISCUSSION AND CONCLUSION 
BTCs are invasive carcinomas deriving
 
from the epithe-
lial lining of the gallbladder and bile ducts. Patients with 
unresectable or metastatic BTC
 
have a poor prognosis with a 
median OS <1 year [16].  
Recently, a pooled analysis was conducted between 1999 
and 2006
 
on 104 chemotherapy trials
 
involving 1,368 BTC 
patients. This analysis underlined a biologic difference be-
tween colangiocarcinoma
 
and gallbladder carcinoma and 
described gemcitabine as
 
the most active agent [17]. Pre-
clinical and translational data suggest that
 
nucleoside trans-
porters, in particular hENT1, play an important role in pre-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Time To Progression in BTC patients receiving gemcitabine-based therapy according to hENT1 expression levels by tumor cells. 
The median time to progression period for positive and negative hENT1 staining patients was 6.33 months and 2.83 months, respectively 
(p=0.0394). TTP: time to progression; ms: months. 
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dicting clinical outcomes
 
after gemcitabine chemotherapy for 
several types of cancer [9,11,18].  
In many clinical trials conducted in BTC patients, a sig-
nificant but modest efficacy of classical cytotoxic chemo-
therapy has been achieved.
 
Literature data
 
suggest that gem-
citabine and gemcitabine-based platinum regimens
 
offer a 
real but slight advantage over other regimens [2]
1
. Only a 
minority of patients really benefits from chemotherapy in 
term of response rate and mostly in term of survival. For this 
reason, it is now necessary to find molecular or genetic fac-
tors predictive of response to chemotherapy, to better select 
patients and avoid both useless toxicities and increased 
health care costs. 
This represents the first original study demonstrating how 
a molecular marker such as the IHC staining for the hENT1 
protein may carry predictive information in patients with 
metastatic BTC. hENT1 protein expression in our patients 
has not demonstrated prognostic significance. In the sub-
population treated with gemcitabine and capecitabine hENT1 
correlated also with OS. hENT1 is probably able to mediate 
the intracellular transport not only of gemcitabine but also of 
fluoropyrimidines, such as capecitabine [19]. From this point 
of view we can suppose that the correlation between hENT1 
and OS, in this particular subgroup of patients, is linked to 
the potential impact of this chemotherapeutic regimen on 
metastatic BTC patients’ outcome.  
Among the BTCs, there are several differences related
 
to 
disease course, sensitivity to chemotherapy, and molecular 
profiles on the basis of the site of primary tumor: intrahe-
patic,
 
distal biliary tree, or gallbladder. Thus, while these 
different types of BTCs
 
have traditionally been included to-
gether in clinical trials,
 
it would be appropriate to separate
 
these diseases in future studies [20]. 
Evidence of heterogeneity in chemotherapy
 
response, ge-
netics, and OS among the different BTCs on the basis of 
origin suggests
 
that future trials evaluating the predictive role 
of hENT should either stratify these entities or
 
study one 
specific entity in a specific trial. Given the relatively small
 
incidence of these cancers, such a trial design will be a great 
challenge
 
and will require a multicenter design to adequately 
include a statistically representative number of each
 
subtype 
of BTC [16].  
Understanding completely how tumor genetics predicts 
drug sensitivity
 
is a key area to focus on in future trials. 
Whether
 
these assays provide sufficient predictive informa-
tion to guide
 
treatment decisions requires prospective evalua-
tion in randomized
 
clinical trials. However, the present study 
highlights the potential role of hENT1 in predicting gemcit-
abine activity and efficacy and in selecting the subpopulation 
of BTC patients who could benefit from gemcitabine based 
regimes, avoiding futile treatments in potential non-
responder patients.  
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